The region’s pioneering AI-powered healthcare company G42 Healthcare has officially entered into a strategic partnership with world-leading healthcare specialists Bravo Pharma, to bring forth a new era of innovation in the field of omics, clinical genomics sequencing solutions and bioinformatics.
Launched in 2011, UK-based Bravo Pharma has been actively working to better the healthcare sector with state-of-the-art technology, innovative diagnostics, e-health solutions, personalized treatment & high-quality affordable pharmaceuticals to target the development gap faced in the industry.
With worldwide offices and operations across Estonia, Uzbekistan, Uganda, India, USA & Sweden, the healthcare innovator has been providing services that cover the whole medical value chain, including applied research and product development, diagnostic services, treatment, medical production and sales.
G42 Healthcare, the leading Abu Dhabi-based health-tech company, aims to transform the traditional healthcare ecosystem across the region and beyond, by harnessing AI and advanced medical technologies. In line with its mission to unlock the potential of personalized and preventive care, G42 Healthcare has established Biogenix Labs, UAE’s first COVID-19 accredited large-scale throughput laboratory, launched IROS, the region’s first contract research organization for clinical research with and for local populations, and set up the Omics Centre of Excellence, the region’s largest and most technologically advanced Omics facility.
For Bravo Pharma, this strategic partnership with G42 Healthcare signals an increased effort in creating AI-based health services across the region and beyond through best-in-class integrated and multidisciplinary care. With more organizations adopting cloud and data digitization practices, both partners will be collaboratively working to revolutionize healthcare in Central Asia by building highly-efficient clinical reporting systems using AI. Furthermore, its specialization in genome sequencing adds to G42 Healthcare’s AI efficiency to rapidly test more genes, which in turn fastens medical detection and treatment timeline.
Regarding the collaboration, Bravo Pharma CMD Rakesh Pandey stated, “For us, this partnership comes as a step closer to our mission of taking healthcare to the next level. As time and technology advance, we have the duty to provide everyone with the best and leading healthcare possible to ensure the highest quality of life for all. With G42 Healthcare’s AI development and our core pharma and advanced diagnostics competencies, we will be able to spearhead the region’s genome and health data computation processes.”
Kareem Shahin, Chief Business Officer, G42 Healthcare commented, “Joining hands with Bravo Pharma strengthens our unified vision for a more personalized, intelligent and value-based healthcare model. The impactful collaboration will enable us to employ our best in class sequencing technologies to provide clinical genomics sequencing services coupled with clinical reporting and bioinformatics to propel healthcare forward.”
